VILLEJUIF & EVRY, France--(BUSINESS WIRE)--IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in oncology and autism and Gustave Roussy, Europe’s leading oncology center, today announced the creation of the first high-throughput, large-scale, sequencing platform that will allow the orientation of patients enrolled in personalized medicine studies towards the most relevant targeted therapies.
Help employers find you! Check out all the jobs and post your resume.
